Sildenafil (Generic) and Rosuvastatin Interaction: Safety, Risks, and Clinical Guidance

Sildenafil (the generic form of Viagra, also marketed as Revatio at lower doses for pulmonary arterial hypertension) and rosuvastatin (brand name Crestor, a hydrophilic HMG-CoA reductase inhibitor) do not share a metabolic pathway that would cause a clinically meaningful drug-drug interaction. Neither the FDA-approved sildenafil label nor the rosuvastatin label lists the other drug as a contraindication or a dose-adjustment trigger. That does not mean the pairing is risk-free in every patient; it means the two drugs' known pharmacology does not point to a shared mechanism of harm.

The direct answer

Rosuvastatin's dose-adjustment triggers listed on its FDA label involve drugs that inhibit OATP1B1/1B3 transport or are strong CYP3A4/protease-inhibitor combinations (cyclosporine, certain HIV antivirals). Sildenafil is not among them. Sildenafil's own label describes dose adjustment only in the context of strong CYP3A4 inhibitors, alpha-blockers, and nitrates, not statins. Because the two drugs' primary elimination routes are largely non-overlapping, there is no established pharmacokinetic mechanism by which one would meaningfully raise or lower the other's blood level at standard doses. This is a mechanistic inference from labeling and general pharmacology, not a substitute for a dedicated interaction study, since none was located for this review.

Why the pathways don't overlap

Sildenafil is metabolized in the liver predominantly by CYP3A4, with a minor role for CYP2C9. Its active metabolite contributes to the overall effect but does not change the primary enzyme dependency. Rosuvastatin behaves differently from most statins: a large majority of an oral dose is eliminated without being metabolized by CYP enzymes at all, and hepatic uptake instead depends on the OATP1B1 and OATP1B3 transporters. Only a small fraction of rosuvastatin clearance runs through CYP2C9.

This matters because the drugs that genuinely raise rosuvastatin exposure - cyclosporine, certain protease inhibitors, gemfibrozil - work by blocking OATP transport, not by competing for CYP3A4. Sildenafil has not been shown to inhibit OATP1B1/1B3 at doses used clinically, so it cannot reproduce that mechanism. The theoretical CYP2C9 overlap between the two drugs is real but minor for both agents individually, which is why it does not appear as a labeled interaction.

Who actually takes both drugs

Erectile dysfunction and dyslipidemia frequently co-occur because both conditions share vascular risk factors, particularly endothelial dysfunction and atherosclerosis. Men prescribed sildenafil for ED are often, independently, candidates for statin therapy under standard cardiovascular prevention guidelines. This clinical overlap is the practical reason the question comes up so often, even though the pharmacologic answer is straightforward.

Rosuvastatin is one of the most widely prescribed statins in the United States, and it is often selected specifically because it and pravastatin carry the least CYP-dependent metabolism among available statins. That property is an advantage for patients who are also taking a PDE5 inhibitor, since it minimizes even the theoretical overlap that exists with CYP3A4-heavy statins like simvastatin and atorvastatin.

Blood pressure and muscle: the two things that do matter

Blood pressure. Sildenafil can lower systolic blood pressure on its own, an effect that is well documented in its FDA label. Rosuvastatin has no known blood pressure effect. A patient on background antihypertensive therapy may notice a blood-pressure effect from sildenafil, but that effect comes from sildenafil and any other antihypertensive drugs the patient takes, not from rosuvastatin.

Muscle symptoms. Statins as a class carry a known risk of myalgia and, rarely, rhabdomyolysis. This is a class effect tied to statin dose, kidney function, genetic factors affecting statin exposure, and interacting drugs that raise statin blood levels. Whether PDE5 inhibitor use itself changes that risk has not been established by a source this review could verify; no dedicated study on combined sildenafil-rosuvastatin muscle outcomes was confirmed for this draft, and any specific incidence figures should be checked against the primary literature before being repeated to a patient. What is established is that rosuvastatin's own myopathy risk rises with higher doses (the label describes dose-dependent risk, with additional caution advised in patients of Asian descent due to higher drug exposure, and in significant renal impairment), independent of sildenafil use.

Evidence-boundary statement

Established: Neither the FDA-approved sildenafil label nor the FDA-approved rosuvastatin label lists the other drug as a contraindicated combination or a dose-adjustment trigger. The two drugs rely on largely distinct elimination pathways (CYP3A4 for sildenafil; OATP transport for rosuvastatin) as described in their respective labels.

Plausible but unproven: That this pharmacokinetic separation translates into zero measurable clinical difference in muscle symptom rates when the two drugs are combined, versus rosuvastatin alone. This is a reasonable mechanistic inference, not a finding confirmed by a verified head-to-head trial in this review.

Not established from the sources available here: Specific incidence rates, odds ratios, or population-prevalence figures (for example, how often ED and statin prescriptions overlap, or exact myalgia rates with concurrent use) that may circulate in secondary summaries of this topic. Any such number should be checked against its original publication before use in patient counseling.

When a third drug changes the picture

The scenario that deserves real attention is not sildenafil plus rosuvastatin alone, but either drug combined with a third medication that is a genuine CYP3A4 or OATP inhibitor.

Strong CYP3A4 inhibitors (examples include ketoconazole, ritonavir, and clarithromycin) are described on the sildenafil label as requiring a lower starting dose. Separately, the rosuvastatin label caps the dose when combined with cyclosporine or certain HIV protease inhibitor combinations, because those drugs block OATP transport and raise rosuvastatin exposure independently. A patient taking sildenafil, rosuvastatin, and a ritonavir-boosted regimen has two separate dose-adjustment questions to resolve, one for each statin/PDE5 label, not a new interaction created by combining all three.

Reduced kidney function is the other situation that changes rosuvastatin handling regardless of sildenafil use. The rosuvastatin label describes substantially higher drug exposure in significant renal impairment, which is a reason to confirm the rosuvastatin dose is appropriate for kidney function, independent of any decision about sildenafil.

Monitoring and counseling

Routine monitoring for the combination does not exceed what each drug requires on its own:

• Rosuvastatin: baseline lipid panel and follow-up per standard cholesterol-management practice; creatine kinase testing is not routine but is appropriate if a patient reports new muscle pain, tenderness, or weakness; baseline liver enzyme testing is standard practice at initiation.
• Sildenafil for ED: no routine laboratory monitoring is required. For the pulmonary arterial hypertension indication (lower, scheduled dosing), monitoring relates to the underlying condition, not to statin co-therapy.
• Renal function: confirm rosuvastatin dosing is appropriate for the patient's kidney function, since impairment raises rosuvastatin exposure independent of sildenafil.

Patients should still be told, plainly, that sildenafil is absolutely contraindicated with nitrates (including recreational nitrate use) regardless of statin therapy, and that new unexplained muscle pain on a statin warrants a call to the prescriber rather than self-discontinuation or continued use without evaluation.

Evidence-status interaction assessment

Comparison with other statin and PDE5 inhibitor pairings

Not every statin behaves like rosuvastatin when combined with sildenafil. Atorvastatin and simvastatin are metabolized largely by CYP3A4, the same enzyme that clears sildenafil, which creates a theoretical (though generally modest) overlap that does not exist with rosuvastatin. Simvastatin in particular carries an FDA-noted dose restriction at its highest approved dose (80 mg) because of myopathy risk with CYP3A4 inhibitors generally, which is a reason some prescribers favor rosuvastatin or pravastatin, both minimally CYP-dependent, when a patient also needs a PDE5 inhibitor. This is a reasonable pharmacologic preference, not evidence that the atorvastatin or simvastatin combinations are unsafe.

When to seek urgent care

Anyone experiencing sudden vision loss, sudden hearing loss, an erection lasting more than four hours, chest pain, or signs of a severe allergic reaction after taking sildenafil should seek emergency care immediately. Anyone on a statin who develops severe muscle pain, dark urine, or profound weakness should stop the statin and contact a clinician promptly, since these can be signs of rhabdomyolysis regardless of what else the patient is taking.